L. Lopez-Lazaro

发表

Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin.

J. Schellens, J. Beijnen, C. van Kesteren, 2003, Anti-cancer drugs.

In vitro toxicity of ET-743 and aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors. comparison with the clinical results.

J. Bueren, J. Jimeno, G. Faircloth, 2002, European journal of cancer.

A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies.

M. Hidalgo, G. Weiss, H. Rosing, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity

G. Demetri, R. Maki, D. Ryan, 2002, Cancer Chemotherapy and Pharmacology.

Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study

J. Schellens, H. Rosing, J. Beijnen, 2002, Anti-cancer drugs.

Mechanism‐based Pharmacokinetic/Pharmacodynamic Meta‐analysis of Trabectedin (ET‐743, Yondelis) Induced Neutropenia

J. Pérez-Ruixo, A. Soto-Matos, P. Zannikos, 2008, Clinical pharmacology and therapeutics.

Population Pharmacokinetic Meta-Analysis of Trabectedin (ET-743, Yondelis®) in Cancer Patients

J. Pérez-Ruixo, E. Ludwig, A. Soto-Matos, 2007, Clinical pharmacokinetics.

Active Eosinophilic Esophagitis Is Associated with Impaired Elimination of Budesonide by Cytochrome P450 3A Enzymes

A. Straumann, K. Dilger, C. Bussmann, 2013, Digestion.

Pharmacokinetics and pharmacodynamic action of budesonide after buccal administration in healthy subjects and patients with oral chronic graft-versus-host disease.

A. Gratwohl, K. Dilger, J. Finke, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Sensitivity of Pegfilgrastim Pharmacokinetic and Pharmacodynamic Parameters to Product Differences in Similarity Studies

M. Karlsson, E. Plan, J. Nyberg, 2019, The AAPS Journal.

Metabolism of trabectedin (ET-743, Yondelis™) in patients with advanced cancer

J. Schellens, H. Rosing, J. Beijnen, 2007, Cancer Chemotherapy and Pharmacology.

Plitidepsin Has a Cytostatic Effect in Human Undifferentiated (Anaplastic) Thyroid Carcinoma

J. Cameselle-Teijeiro, J. Zalvide, C. Álvarez, 2005, Clinical Cancer Research.

Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies.

E. Raymond, J. Armand, S. Faivre, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized, Double-Blind, Pharmacokinetic Equivalence Trial Comparing DRL-Rituximab With MabThera in Patients With Diffuse Large B-Cell Lymphoma

A. Viswabandya, A. Srivastava, A. Srivastava, 2019, Journal of global oncology.

Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice

J. Schellens, H. Rosing, J. Beijnen, 2010, Investigational New Drugs.

Trabectedin (ET-743, Yondelis™) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype

J. Schellens, J. Beijnen, J. Beumer, 2007, Investigational New Drugs.

Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in man

J. Schellens, H. Rosing, J. Beijnen, 2001, Anti-cancer drugs.

A comparative pharmacokinetic study of DRL_BZ, a candidate biosimilar of bevacizumab, with Avastin® (EU and US) in healthy male subjects

C. Wynne, L. Lopez-Lazaro, C. Schwabe, 2018, British journal of clinical pharmacology.

In vitro hematotoxicity of Aplidine on human bone marrow and cord blood progenitor cells.

J. Bueren, J. Jimeno, G. Faircloth, 2001, Toxicology in vitro : an international journal published in association with BIBRA.

Acute myocardial infarction associated with sildenafil

L. Lopez-Lazaro, A. Portolés-Pérez, E. Vargas‐Castrillón, 1998, The Lancet.

Switching from an analogous to a stable isotopically labeled internal standard for the LC-MS/MS quantitation of the novel anticancer drug Kahalalide F significantly improves assay performance.

J. Schellens, H. Rosing, J. Beijnen, 2004, Biomedical chromatography : BMC.

Mass balance and metabolism of the antimalarial pyronaridine in healthy volunteers

C. A. Morris, D. Jung, S. Dueker, 2015, European Journal of Drug Metabolism and Pharmacokinetics.

Quantitative analysis of ES-285, an investigational marine anticancer drug, in human, mouse, rat, and dog plasma using coupled liquid chromatography and tandem mass spectrometry.

J. Schellens, H. Rosing, J. Beijnen, 2003, Journal of mass spectrometry : JMS.

Phase I Clinical and Pharmacokinetic Study of Kahalalide F in Patients with Advanced Androgen Refractory Prostate Cancer

T. D. de Reijke, J. Schellens, J. Beijnen, 2005, Clinical Cancer Research.

Quantitative analysis of the novel depsipeptide anticancer drug Kahalalide F in human plasma by high-performance liquid chromatography under basic conditions coupled to electrospray ionization tandem mass spectrometry.

J. Schellens, H. Rosing, J. Beijnen, 2002, Journal of mass spectrometry : JMS.

Chemical and enzymatic stability of a cyclic depsipeptide, the novel, marine-derived, anti-cancer agent kahalalide F

J. Schellens, J. Beijnen, J. Jimeno, 2001, Anti-cancer drugs.

Evaluation of the use of in vitro methodologies as tools for screening new compounds for potential in vivo toxicity.

J. Jimeno, G. Faircloth, L. Lopez-Lazaro, 2001, Toxicology in vitro : an international journal published in association with BIBRA.